Skip to main content
Bioton S.A. logo

Bioton S.A. — Investor Relations & Filings

Ticker · BIO ISIN · PLBIOTN00029 LEI · 259400I5R1L3OPCGII81 WAR Manufacturing
Open in API
Filings indexed 697 across all filing types
Latest filing 2024-11-08 Interim / Quarterly Rep…
Country PL Poland
Listing WAR BIO

About Bioton S.A.

https://bioton.com/en/

Bioton S.A. is a biotechnology company focused on providing comprehensive solutions for diabetes care. The company's core activity is the development and production of recombinant human insulin, positioning it as a significant commercial manufacturer globally. Its operations cover the full biotechnological process, from DNA research and development to the manufacturing and marketing of finished medicinal products. The product portfolio is centered on various forms of insulin and is complemented by modern automatic injection systems designed to facilitate effective diabetes treatment for patients.

Recent filings

Filing Released Lang Actions
Wybrane dane skonsolidowane Q3 2024
Interim / Quarterly Report Classification · 100% confidence The document contains detailed consolidated financial data (balance sheet and income statement items) for the period ending 30.09.2024 compared to 30.09.2023 and 31.12.2023. It provides substantive financial metrics such as net revenue, operating profit, cash flows, and earnings per share. Since it covers a period shorter than a full fiscal year (nine months) and contains actual financial statements/data, it is classified as an Interim/Quarterly Report. 9M 2024
2024-11-08 Polish
Wybrane dane jednostkowe Q3 2024
Interim / Quarterly Report Classification · 100% confidence The document contains detailed financial statements (balance sheet and income statement data) for the period 01.01.2024 - 30.09.2024 compared to the previous year. It provides substantive financial data including revenue, profit/loss, cash flows, and assets, which qualifies it as an interim financial report rather than just an announcement or a summary. 9M 2024
2024-11-08 Polish
Informacja dodatkowa do raportu Q3 2024
Interim / Quarterly Report Classification · 100% confidence The document is a detailed quarterly financial report for the BIOTON S.A. Group for the third quarter of 2024. It contains comprehensive financial data, including consolidated income statements, segment reporting, balance sheet information, and management's discussion of financial results and accounting principles. It is not a mere announcement or certification, but the actual financial report itself, fitting the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-08 Polish
Sprawozdanie finansowe Q3 2024 Grupa kapitałowa Bioton
Interim / Quarterly Report Classification · 100% confidence The document is a 'Consolidated Extended Quarterly Report' (Skonsolidowany rozszerzony raport kwartalny) for the period ending September 30, 2024. It contains detailed financial statements, including the Consolidated Income Statement, Consolidated Balance Sheet, and Consolidated Statement of Comprehensive Income. As it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2024
2024-11-08 Polish
Zmiana terminu publikacji raportu okresowego za III kwartał 2024 roku - Content (PL)
Report Publication Announcement Classification · 98% confidence The document text is very short (501 characters) and explicitly states that the company is informing about a change in the publication date for its extended consolidated quarterly report for Q3 2024 (from 31.10.2024 to 8.11.2024). This is an announcement about the timing of a future report release, not the report itself. According to Rule 2 (The 'Menu vs Meal' Rule), a short announcement regarding the publication timing of a report should be classified as a Report Publication Announcement (RPA). The legal basis cited is related to ongoing reporting requirements, confirming its nature as a regulatory announcement.
2024-10-28 Polish
Ujawnienie opóźnionej informacji poufnej dotyczącej negocjacji związanych ze zmianą umowy dostawy zawartej z Nemera Szczecin Sp. z o.o. oraz treść Aneksu. - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a formal notification from Bioton S.A. (Emitent) regarding the delayed disclosure of inside information, referencing Article 17(4) of the EU Market Abuse Regulation (MAR). The core content details the finalization and signing of an amendment (Aneks) to a supply agreement with Nemera, outlining significant changes to product supply, volumes, exclusivity territories (Poland, Bangladesh, Belarus, etc.), and contract duration (until Dec 31, 2027). This type of announcement, detailing material changes in business operations, contracts, or strategic agreements, falls under general regulatory disclosures. Since it is not a specific financial report (10-K, IR, ER), a management discussion (MDA), or a director dealing report (DIRS), the most appropriate general category for significant, non-standard regulatory updates that impact business operations is 'Regulatory Filings' (RNS). The document length is short (2339 chars), but it is the primary disclosure itself, not an announcement *about* another report.
2024-09-24 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.